On July 22, 2024, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Foreseen Technology (Beijing) Co., Ltd. ("Foreseen") jointly announced that the First-in-Class antibody-drug conjugate (ADC, FS001/ESG408), which was previously co-developed by both parties, has been licensed to Ipsen Pharma SAS ("Ipsen") of France. Foreseen, as the contracting representative, signed the agreement with Ipsen on July 11, 2024, granting Ipsen global exclusive rights to develop, produce, and commercialize the ADC.

Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced today that it has entered into an ADC platform technology licensing agreement with Sidewinder Therapeutics, Inc. ("Sidewinder") of the United States. Under the licensing agreement, Escugen has granted Sidewinder a global exclusive license to use its ADC technology platform, EZWi-Fit®, for the development of ADC products targeting specific antigens.